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Abstract
Arterial medial calcification (AMC), the deposition of hydroxyapatite in the medial
layer of the arteries, is a known risk factor for cardiovascular events. Oxidative
stress is a known inducer of AMC and endogenous antioxidants, such as glutathione
(GSH), may prevent calcification. GSH synthesis, however, can be limited by cysteine
levels. Therefore, we assessed the effects of the cysteine prodrug 2‐oxothiazolidine‐
4‐carboxylic acid (OTC), on vascular smooth muscle cell (VSMC) calcification to
ascertain its therapeutic potential. Human aortic VSMCs were cultured in basal or
mineralising medium (1mM calcium chloride/sodium phosphate) and treated with
OTC (1–5mM) for 7 days. Cell‐based assays and western blot analysis were per-
formed to assess cell differentiation and function. OTC inhibited calcification ≤90%,
which was associated with increased ectonucleotide pyrophosphatase/phospho-
diesterase activity, and reduced apoptosis. In calcifying cells, OTC downregulated
protein expression of osteoblast markers (Runt‐related transcription factor 2 and
osteopontin), while maintaining expression of VSMC markers (smooth muscle pro-
tein 22α and α‐smooth muscle actin). GSH levels were significantly reduced by 90%
in VSMCs cultured in calcifying conditions, which was associated with declines in
expression of gamma‐glutamylcysteine synthetase and GSH synthetase. Treatment
of calcifying cells with OTC blocked the reduction in expression of both enzymes and
prevented the decline in GSH. This study shows OTC to be a potent and effective
inhibitor of in vitro VSMC calcification. It appears to maintain GSH synthesis which
may, in turn, prevent apoptosis and VSMCs gaining osteoblast‐like characteristics.
These findings may be of clinical relevance and raise the possibility that treatment
with OTC could benefit patients susceptible to AMC.
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1 | INTRODUCTION
Vascular calcification (VC) is a common complication of chronic
kidney disease (CKD), diabetes, and atherosclerosis. It is the patho-
logical deposition of the calcium phosphate mineral, hydroxyapatite,
in the intimal and/or medial layers of the arterial wall (Durham,
Speer, Scatena, Giachelli, & Shanahan, 2018). Arterial medial calcifi-
cation (AMC), defined as calcification within the tunica media of
blood vessels, is associated with arterial stiffness, reduced blood
flow, heart failure, and mortality (Vervloet & Cozzolino, 2017). In
CKD, coronary artery calcification is six times more prevalent than in
the general population (Kramer, Toto, Peshock, Cooper, & Victor,
2005; Roy, Cespedes, Li, Choi, & Budoff, 2011), and is known to
contribute to nearly 50% of deaths in patients with end‐stage renal
disease due to cardiovascular complications (Chen et al., 2017;
Parikh et al., 2006). Despite these known adverse effects of AMC,
there are currently no specific treatments to prevent or retard cal-
cium deposition. Given that the prevalence of diseases associated
with AMC are on the rise (Heidenreich et al., 2011; Hoerger
et al., 2015; Rowley, Bezold, Arikan, Byrne, & Krohe, 2017), novel
therapies to manage this condition are acutely required.
Currently, the mechanisms leading to AMC are insufficiently
understood. However, the traditional concept of passive calcification
resulting from elevated phosphate and calcium levels is now known
to be false (Mizobuchi, Towler, & Slatopolsky, 2009). Instead, AMC is
considered an active cell‐mediated process, sharing some outward
similarities with bone mineralisation, driven by vascular smooth
muscle cells (VSMCs). Mechanisms considered to play a role in VC
include loss of calcification inhibitors (e.g., pyrophosphate [PPi], ec-
tonucleotide pyrophosphatase/phosphodiesterase (NPP), fetuin A,
and matrix gla protein), gain of calcification inducers (e.g., tissue
nonspecific alkaline phosphatase [TNAP]), and apoptosis (Mizobuchi
et al., 2009; Patel, Bourne, Davies et al., 2019; Patel, Bourne, Millan
et al., 2019). In addition, when maintained in a calcifying environment
(elevated calcium and/or phosphate), VSMCs undergoes phenotypic
transdifferentiation to gain limited osteoblast‐like characteristics
(Patel, Bourne, Davies et al., 2019).
Oxidative stress, the imbalance between production and accu-
mulation of reactive oxygen species (ROS), is a known mediator of
AMC (Mody, Parhami, Sarafian, & Demer, 2001; Sudo, Sato, Azechi, &
Wachi, 2015; Zhao et al., 2011). ROS, such as hydrogen peroxide, have
been shown to promote VSMC calcification in vitro via VSMC trans-
differentiation to an osteoblast‐like cell (Byon et al., 2008; Mody
et al., 2001). In addition, oxidative stress has been implicated in the
induction of VSMC apoptosis (Cui, Li, Chang, Cong, & Hao, 2017),
which could play a role in AMC pathogenesis, as mentioned above.
Antioxidants, which inhibit ROS and oxidative stress, can protect
against VSMC calcification. Plant polyphenols, such as curcumin and
silybin, known to have antioxidant properties, have been shown to
reverse VSMC calcification in vitro by reducing ROS levels and VSMC
transdifferentiation (Roman‐Garcia, Barrio‐Vazquez, Fernandez‐
Martin, Ruiz‐Torres, & Cannata‐Andia, 2011). The synthetic vitamin E
analogue, Trolox, has also been found to reverse VSMC phenotypic
changes and inhibit calcification in vitro as well as in vivo using a
uremic calcification model (Mody et al., 2001; S. Yamada et al., 2012).
In addition to exogenous antioxidants, cells have evolved mechan-
isms to counteract localised increases in oxidative stress. One such
example is glutathione (GSH), which acts as a reducing agent or binds to
electrophiles to neutralise ROS (Lushchak, 2012; Siauciunaite, Foulkes,
Calabrò, & Vallone, 2019). Intracellular levels of GSH range from 0.5 to
10mM and it is the most abundant low‐molecular‐mass thiol in cells
(Lushchak, 2012). Though synthesised in nearly every cell, GSH is pro-
minently produced in the liver. GSH synthesis from glutamate, cysteine,
and glycine requires two enzyme reactions, the first (rate‐limiting)
gamma‐glutamylcysteine synthetase (GCL) and, subsequently, glu-
tathione synthetase (GSS). In addition to GCL, another rate‐limiting
factor for GSH synthesis is cysteine availability (Lu, 2009; Wu, Fang,
Yang, Lupton, & Turner, 2004). Prodrugs of cysteine, such as
2‐oxothiazolidine‐4‐carboxylic acid (OTC) and N‐acetylcysteine have
been shown to increase cellular cysteine and GSH levels (Gould &
Pazdro, 2019). OTC is converted to cysteine via intracellular
5‐oxoprolinase and has been shown to be more effective than
N‐acetylcysteine in replenishing GSH levels (Williamson, Boettcher, &
Meister, 1982). In clinical trials, cysteine levels are elevated in HIV
patients given OTC at doses up to 100mg/kg iv (Kalayjian et al., 1994).
In patients with CKD on peritoneal dialysis, OTC (500mg orally, every
8 hr for 14 days), increased circulating GSH levels (Moberly et al., 1998).
Furthermore, OTC reversed dialysate‐induced acceleration of cellular
senescence and inflammation in peritoneal mesothelial cells
(Sosinska‐Zawierucha, Mackowiak, Begier‐Krasinska, Hoppe, &
Breborowicz, 2018). OTC (63mg/kg iv, every 8 hr for 10 days) also
mediated GSH repletion in patients with acute respiratory distress syn-
drome and led to reductions in acute lung injury (Bernard et al., 1997).
Given CKD and diabetes have been associated with elevated
oxidative stress (Dounousi et al., 2006; Seghrouchni et al., 2002),
ROS may play a pivotal role in causing AMC in these patients.
Therefore, reductions in oxidative stress via intracellular anti-
oxidants, such as GSH, may serve to inhibit or slow calcification
progression. Here, we examine the effects of the cysteine prodrug
OTC on VSMC calcification and elucidate the potential effects of
GSH in AMC.
2 | MATERIALS AND METHODS
2.1 | Reagents
Tissue culture reagents were purchased from Life Technologies
(Paisley, UK). Unless otherwise stated, chemicals and reagents were
purchased from Sigma‐Aldrich (Poole, UK).
2.2 | VSMC calcification assay
Human aortic VSMCs (Lonza, Slough, UK) were cultured in Dulbec-
co's modified Eagle's medium (DMEM) with L‐glutamine,
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supplemented with 10% foetal calf serum, 100 U/ml penicillin, and
100 µg/ml streptomycin (complete mixture abbreviated to DMEM).
Passages 5–8 cells were utilised and seeded into 24‐well plates at a
density of 5 × 104 cells/well. VSMCs were cultured in either control
medium (DMEM) or calcifying medium (DMEM+ 1mM calcium
chloride and sodium phosphate), for up to 7 days at 37°C in 5% CO2,
with half medium changes taking place every 3–4 days. Cells were
treated with 1‐5mM 2‐oxo‐thiazolidine‐4‐carboxylate (Alfa Aesar,
Heysham, UK), or 1–20 µM l‐buthionine‐sulfoximine throughout.
Stock solutions of 2‐oxo‐thiazolidine‐4‐carboxylate and l‐buthionine‐
sulfoximine were prepared in water.
2.3 | Determination of VSMC calcification
To quantify calcification, calcifying VSMCs cultured for 7 days were
washed twice with phosphate‐buffered saline (PBS), then incubated
with 0.6M hydrochloric acid at room temperature for 24 hr to so-
lubilise deposited calcium. Calcium content was measured color-
imetrically by stable interaction with o‐cresolphthalein using the
Calcium Colorimetric Assay Kit (Sigma‐Aldrich), as per manu-
facturer's instructions. Calcium content was corrected for total
protein concentration using the Bradford assay.
For visualisation of calcium deposition, monolayers were fixed
with 2.5% glutaraldehyde, and stained for calcium with alizarin red S
(1% solution wt/vol in water) for 5min and rinsed with 50% ethanol
to remove the excess stain. In addition to alizarin red, which mea-
sures general calcium deposition, the OsteoImage (Lonza, Slough,
UK) Mineralisation Assay Kit was also utilised. This assay utilises a
fluorescent stain that binds to hydroxyapatite, the calcium‐
phosphate salt of bone mineral. Assays were performed as per
manufacturer's instructions. Briefly, fixed cells were initially washed
in wash buffer and incubated with staining reagent for 30min at
room temperature in the dark. Cells were subsequently incubated
with wash buffer for 5min and rinsed; this was repeated three times.
After the final wash, wash buffer was added to keep monolayers wet
for microscopy. Hydroxyapatite deposition was visualised using an
EVOS FL Imaging System (Life Technologies), with a GFP light cube
(Ex: 470/22 nm, Em: 510/42 nm).
2.4 | Determination of total TNAP and NPP activity
TNAP enzyme activity was assessed in VSMCs cultured for 7 days,
utilising a Colorimetric Assay Kit (Anaspec, Fremont), as previously
described (Orriss, Key et al., 2012). Briefly, monolayers were washed
in PBS and collected in water using a scraper. Samples were cen-
trifuged at 500g at 4°C, and TNAP activity of the supernatant mea-
sured using a Clariostar microplate reader (Aylesbury, UK) set at
405 nm. TNAP activity was normalised to cell protein using the
Bradford assay.
Total cellular NPP activity was assessed as previously described
(Patel, Bourne, Davies et al., 2019). In brief, VSMCs cultured for
7 days were lysed in a buffer containing 1% Triton X‐100 in 0.2M
Tris base with 1.6 mM MgCl2, pH 8.1. Following centrifugation at
500g at 4°C, NPP activity of collected supernatants was measured
on a Clariostar microplate reader set at 405 nm using 5mM
p‐nitrophenyl‐thymidine 5′‐monophosphate as a substrate. The total
protein in cell lysates was determined using the Bradford assay.
2.5 | Cell number and viability assay
Cell number and viability were determined at Day 7 of culture using
the CytoTox 96® Colorimetric Cytotoxicity Assay (Promega,
Southampton, UK), as described previously (Patel, Bourne, Davies
et al., 2019). Briefly, cell supernatants were collected to determine
medium lactate dehydrogenase (LDH) levels (cell viability); to es-
tablish total cellular LDH levels, cells were lysed with 1% Triton
X‐100 in water for 1 hr. Cell supernatant and lysates were measured
as per manufacturer's instructions using a Clariostar microplate
reader set at 490 nm. Cell lysate absorbance values were compared
to a standard curve of known cell density, allowing quantification of
cell number. Cell viability was calculated by expressing medium LDH
as a percentage of the total cellular LDH cell.
2.6 | Quantification of apoptosis by flow cytometry
VSMC were cultured in the noncalcifying or calcifying medium for
7 days. Apoptosis was assessed via flow cytometry using an annexin
V antibody conjugated to fluorescein (Life Technologies), as per
manufacturer's instructions. Briefly, cells were detached using
trypsin‐ethylenediaminetetraacetic acid (EDTA; 0.05%) and the re-
sultant pellet washed in ice‐cold PBS. This suspension was cen-
trifuged and resuspended in 1X annexin‐binding buffer (Life
Technologies). A sample of this suspension was incubated with the
annexin V antibody for 15min and analysed using a Guava easyCyte
8HT Flow Cytometer (Merck‐Millipore, Watford, UK). Data were
processed to calculate percentage apoptosis using Flowing Software
(version 2.5.1; Turku University, Finland).
2.7 | Western blot analysis
Protein was extracted from VSMCs cultured in control and calcifi-
cation medium at Days 4 and 7 of culture. Cell monolayers were
lysed in ice‐cold radioimmunoprecipitation lysis buffer (50mM tris
hydrochloride, pH 7.4, 150mM sodium chloride, 5 mM EDTA, and
0.1% sodium dodecyl sulfate [SDS]), with protease inhibitor cocktail
(Sigma‐Aldrich). Cell homogenates were sonicated for 5min and
centrifuged at 10,000 rpm at 4°C, before protein concentration de-
termination using the Bradford assay. Loading samples were pre-
pared using Bolt lithium dodecyl sulfate sample buffer and Bolt
sample reducing agent (Life Technologies), as per manufacturer's
instructions. Samples were denatured at 70°C for 10min.
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Protein samples were loaded into Bolt Bis‐Tris Plus Gels (8%) (Life
Technologies), and run alongside a protein ladder (Precision Plus
Protein Kaleidoscope Standard; Bio‐Rad, Watford, UK). Gel electro-
phoresis was run at 160 V for 40min in Bolt MES SDS running buffer
(Life Technologies). Protein samples were subsequently transferred
onto a nitrocellulose membrane using the iBlot 2 Transfer System
(Life Technologies). Membranes were then blocked with 5% nonfat
milk for 1 hr, and, subsequently, incubated with Runt‐related tran-
scription factor 2 (Runx2), α‐smooth muscle actin (ACTA2; Cell Sig-
naling Technology, London, UK), smooth muscle protein 22α
(SM22α), glutamate‐cysteine ligase (glutamate‐cysteine ligase cata-
lytic subunit [GCLC]), GSS (Abcam, Cambridge, UK), or osteopontin
(OPN; Bio‐Rad, Kidlington, UK) antibodies overnight at 4°C. After
washing, blots were incubated in horseradish peroxidase (HRP)‐
conjugated secondary antibodies (Cell Signaling Technology, London,
UK/Bio‐Rad, Kidlington), for 1 hr at room temperature. A β‐actin‐
HRP conjugate antibody (Abcam) was used as a loading control, with
blots incubated for 1 hr at room temperature. A peroxidase detection
system (Radiance ECL; Azure Biosystems, Dublin) and myECL Imager
(Thermo Fisher Scientific, Hemel Hempstead, UK) were used for the
visualisation of immunoreactivity.
2.8 | Measurement of total GSH
Total GSH was assessed in VSMCs cultured in control or calcification
medium for 7 days, using a colorimetric assay based on a method by
Rahman, Kode, and Biswas (2006). After the removal of culture
media, monolayers were washed with PBS and subsequently col-
lected in PBS using a cell scraper. Samples were centrifuged at
1,000g at 4°C for 5min, after which the pellet was washed in fresh
PBS and resuspended. The pellet was resuspended in ice‐cold lysis
buffer (0.1% Triton‐X and 0.6% sulfosalicylic acid in 0.1M potassium
phosphate buffer with 5mM EDTA, pH 7.5), and homogenised with a
Teflon pestle. Lysed cells were subsequently sonicated for 2–3min
with vortexing every 30 s. Following centrifugation at 3,000g at 4°C
for 5min, total GSH of collected supernatants was measured fol-
lowing addition of 5,5‐dithiobis(2‐nitrobenzoic acid), GSH reductase,
and NADPH using a Clariostar microplate reader set at 412 nm.
Absorbance values were compared to a standard curve of known
GSH concentration and corrected for total protein concentration
using the Bradford assay.
2.9 | Statistical analysis
Data were analysed using GraphPad Prism 7 software (San Diego,
CA). Statistical comparisons were made using a T test or a one‐way
analysis of variance with a post hoc Bonferroni correction for mul-
tiple comparisons. Results are expressed as mean ± standard error of
the mean for six technical replicates. Results are representative of
experiments performed at least three times.
3 | RESULTS
3.1 | OTC inhibits VSMC calcification
VSMCs cultured with calcifying medium (1mM Ca/P) for 7 days, and
stained with alizarin red, showed abundant regions of calcification
(Figure 1a). To ascertain whether this deposition was similar in
composition to in vivo calcification, calcifying cells were stained with
the hydroxyapatite specific fluorescence stain OsteoImageTM.
Fluorescence staining (Figure 1e) confirmed calcification of VSMCs
as seen with alizarin red.
The addition of OTC to calcifying VSMCs led to a strong in-
hibition of calcification at concentrations of ≥2.5 mM (Figures 1b–d
and 1f–h). Quantification of calcium deposition showed up to 90%
inhibition in OTC‐treated cells, compared to untreated cells
(Figure 2).
F IGURE 1 OTC inhibits VSMC calcification. The pictures show phase contrast (alizarin red stained) and fluorescent (OsteoImageTM) images
of VSMCs after 7 days in culture. Abundant regions of calcification are present in calcium/phosphate treated cells (a), the deposition was
confirmed to be hydroxyapatite utilising the specific fluorescent dye (e). Treatment with OTC inhibited calcification with increasing dose (b–d,
f–h). Scale bars: Phase contrast and fluorescent microscopy images = 250 µm. OTC, 2‐Oxothiazolidine‐4‐carboxylic acid
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3.2 | OTC treatment increased total NPP activity
while reducing TNAP activity
PPi, the potent inhibitor of calcification, acts via the prevention of
hydroxyapatite formation and crystal growth. The inhibitor is
formed by NPP, which hydrolyses nucleotide triphosphates to
generate PPi (Orriss, Arnett, & Russell, 2016; Villa‐Bellosta &
Egido, 2015). PPi can be degraded to phosphate by TNAP leading to
the induction of mineralisation, in addition to the removal of the
inhibitor (Villa‐Bellosta & Egido, 2015). To establish whether OTC
affects NPP and/or TNAP activity, calcifying VSMCs were treated
with OTC for 7 days and enzyme activity assessed. OTC
concentration‐dependently enhanced the activity of NPP but de-
cresed that on TNAP by about threefold when compared to re-
spective controls (Figure 3).
3.3 | OTC inhibits apoptosis and enhances cell
viability in calcifying VSMCs
OTC concentration‐dependently increased cell number by up to
40%, compared to untreated calcifying cells (Figure 4a); this was
associated with a rise in cell viability (measured as the percentage
of dead cells). OTC treatment reduced the percentage of dead cells
by up to 85%, compared to untreated calcifying cells (Figure 4b). To
ascertain whether the effects of OTC on cell number and viability
were mediated via inhibition of apoptosis, a known factor in the
induction of AMC (Proudfoot, 2019), the early apoptosis marker
annexin V was assessed utilising flow cytometry. Apoptosis was
significantly increased by 75% in calcifying VSMCs when compared
to noncalcifying cells. Treatment with OTC (2.5 mM) decreased
apoptosis in calcifying cells, reducing this back to control levels
(Figure 4b).
3.4 | OTC reverses acquisition of osteoblast‐like
characteristics in calcifying VSMCs
Previous studies have shown that calcification is associated with
VSMCs gaining limited osteoblast‐like characteristics (e.g., Runx2 and
OPN expression), and reduced expression of VSMC markers (SM22α
and ACTA2) (Patel, Bourne, Davies et al., 2019; Steitz et al., 2001). At
Days 4 and 7 of culture, expression of Runx2 and OPN were
F IGURE 2 Inhibition of VSMC calcification by OTC. Calcium
deposition was inhibited concentration dependently by OTC in
calcifying VSMCs treated with the drug for 7 days. Values are
mean ± standard error of the mean (n = 6 replicate wells), ***p < .001.
OTC, 2‐oxothiazolidine‐4‐carboxylic acid
F IGURE 3 Reduced TNAP and increased NPP activity with OTC treatment. Calcifying VSMCs treated with OTC for 7 days exhibited a
threefold reduction in TNAP activity (a) and a threefold increase in NPP activity (b) compared to untreated cells. Values are mean ± standard
error of the mean (n = 6 replicate wells), ***p < .001, **p < .01. NPP, ectonucleotide pyrophosphatase/phosphodiesterase;
OTC, 2‐oxothiazolidine‐4‐carboxylic acid; TNAP, tissue nonspecific alkaline phosphatase; VSMC, vascular smooth muscle cell
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upregulated, while SM22α and ACTA2 were downregulated in cal-
cifying VSMCs when compared to noncalcifying cells. The addition of
OTC (2.5 mM) to calcifying cells reversed these effect, particularly at
Day 7, leading to a similar expression of both osteoblast and VSMC
markers to those seen in noncalcifying cells (Figure 5).
3.5 | Diminished GSH levels promote calcification
To ascertain whether calcification and OTC treatment are associated
with changes in GSH levels, intracellular GSH was assessed in VSMCs
cultured for 7 days. GSH levels were reduced by 90% in calcifying
cells compared to noncalcifying VSMCs. Treatment of calcifying cells
with OTC (2.5 mM) rescued GSH levels to those seen in controls
(Figure 6a).
Given the reduction in GSH levels in calcifying VSMC, the effects
of diminished GSH on calcium deposition were assessed. Calcifying
VSMCs were treated with the GSH depletion agent l‐buthionine‐
sulfoximine, an inhibitor of GCL (Bailey, 1998). l‐buthionine‐
sulfoximine (≥10 μM) increased calcification by up to 50% compared
to untreated cells. Addition of OTC (2.5 mM) to these cultures
abolished increases in calcification due to l‐buthionine‐sulfoximine
(Figure 6b). From this, we sought to ascertain whether OTC regulates
the expression of both GSH synthesis enzymes, namely GCL and GSS.
At Day 7 of culture, expression of GCL (measured via GCLC) and GSS
were downregulated in calcifying VSMCs when compared to non-
calcifying cells. The addition of OTC (2.5 mM) reversed the inhibition
in protein expression and restored levels similar to those seen in
noncalcifying cells (Figure 6c).
4 | DISCUSSION
AMC, common in patients with CKD, diabetes, and atherosclerosis,
has been linked to elevated oxidative stress (Mody et al., 2001; Sudo
et al., 2015; Zhao et al., 2011). Antioxidants, which inhibit ROS and
F IGURE 4 OTC increases VSMC number and viability while reducing apoptosis. OTC concentration‐dependently increased VSMC number
by up to 40% compared to untreated cells (a). Treatment with OTC was associated with an increase in VSMC viability; the percentage of dead
cells was up to 85% lower in treated cells compared to untreated (b). The culture of VSMCs in calcifying conditions was associated with a 75%
increase in apoptosis when compared to noncalcifying cells. Treatment with OTC (2.5 mM) led to a reduction in apoptosis to levels seen in
control noncalcifying cells (c). Values are mean ± standard error of the mean (n = 6 replicate wells), *p < .05, **p < .01, ***p < .001.
OTC, 2‐oxothiazolidine‐4‐carboxylic acid; VSMC, vascular smooth muscle cell
F IGURE 5 OTC reverses the acquisition of osteoblast‐like
phenotype in calcifying VSMCs. At Days 4 and 7 of culture,
expression of VSMC markers (SM22α and ACTA2) were
downregulated in calcifying VSMCs (Cal) compared to noncalcifying
controls (NC). In contrast, osteoblast markers (Runx2 and OPN) were
upregulated. Treatment of calcifying VSMCs with OTC (2.5 mM;
+OTC) reversed these changes. Blots shown are representative of
experiments performed three times with different protein sets.
ACTA2, α‐smooth muscle actin; OPN, osteopontin;
OTC, 2‐oxothiazolidine‐4‐carboxylic acid; Runx2, Runt‐related
transcription factor 2; SM22α, smooth muscle protein 22α
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reduce oxidative stress, have been shown to inhibit calcification.
Given the lack of treatment options currently available for VC,
boosting intracellular antioxidants, such as GSH, may provide a novel
treatment option. We have demonstrated, for the first time, that the
cysteine prodrug OTC strongly inhibits VSMC calcification in vitro.
This inhibitory effect was associated with increased total NPP ac-
tivity as well as prevention of apoptosis and VSMC gaining
osteoblast‐like characteristics. These effects were subsequently
found to be associated with preserving intracellular GSH levels by
maintaining GSH synthesis enzyme expression, in addition to the
ability of OTC to boost cysteine levels and thus GSH formation.
Initial staining of VSMC cultures with alizarin red highlighted
significant calcium deposition in calcifying VSMCs. Alizarin red is,
however, a nonspecific calcium stain, which together with excessive
phosphate levels used in some VSMC methods, can lead to calcium/
phosphate precipitation and overestimation of quantified calcifica-
tion (Orriss, Taylor, & Arnett, 2012). To ascertain whether our cal-
cifying VSMCs form hydroxyapatite, the calcium phosphate mineral
found in bone, monolayers were stained with the hydroxyapatite
specific OsteoImage fluorescent dye. The fluorescent dye exhibited a
similar pattern of staining to that with alizarin red, confirming that
our model is appropriate for investigating in vitro calcification. Uti-
lising this model, OTC (≥2.5 mM) was found to strongly inhibit cal-
cification by up to 90%, suggesting it to be a potent inhibitor of in
vitro VSMC calcification.
Given the inhibitory effect of OTC on calcification and that OTC
contains a carboxylic acid moiety, OTC may simply elicit its inhibitory
effect by either inhibition of Ca/P precipitation or via a reduction in
extracellular pH. However, M. Yamada et al. (2013) showed
N‐acetylcysteine (similar to OTC in structure), promoted in vitro bone
formation in osteoblasts, and accelerated bone repair in vivo. Given
calcium phosphate mineral in bone and calcifying VSMCs is the same
(hydroxyapatite), it would be unlikely that OTC affects precipitation.
pH has been shown to be an important regulator of bone formation and
small changes in pH (from 7.4 to 6.9) can inhibit physiological bone
mineralisation (Arnett, 2010; Brandao‐Burch, Utting, Orriss, & Arnett,
2005). Given that N‐acetylcysteine can promote bone formation and
itself contains a carboxylic acid moiety, pH is therefore unlikely to play
a role. To validate this, calcifying VSMCs were treated with a stock
solution with a similar pH to that of OTC but this did not induce any
calcification of VSMCs even after 7 days of culture (data not shown).
A key regulator of mineralisation is the ratio of phosphate and
PPi within the local environment (Fleisch & Bisaz, 1962). As men-
tioned above, NPP hydrolyses nucleotide triphosphates to generate
PPi, while TNAP degrades PPi to phosphate (Orriss et al., 2016;
Villa‐Bellosta & Egido, 2015). Here, TNAP activity was reduced
whereas NPP activity increased by about threefold in OTC‐treated
cells when compared to untreated controls. Given the similar chan-
ges in TNAP and NPP activity, it could be argued that OTC may not
cause any overall change in pyrophosphate levels. However, we
previously showed that TNAP activity in calcifying VSMCs was
100‐fold lower than in bone‐forming osteoblasts (Patel, Bourne, Davies
et al., 2019). Thus, it is unlikely that TNAP activity plays a significant role
in mediating VSMC calcification in vitro but the increased NPP activity
induced by OTC is likely to lead to a larger pool of pyrophosphate and
subsequent inhibition of mineralisation.
F IGURE 6 Diminished GSH levels promote calcification in VSMC. GSH was reduced by 90% in calcifying VSMCs compared to noncalcifying
cells; OTC (2.5 mM) reversed this decline (a).l‐buthionine‐sulfoximine, a specific inhibitor of GCL, increased calcification by up to 50% compared
to untreated cells. OTC (2.5 mM) inhibited this increase in calcification (b). Expression of protein for glutamate‐cysteine ligase catalytic subunit
(GCLC) and for GSS were downregulated in calcifying VSMC (Cal) compared to noncalcifying controls (NC). Treatment of calcifying VSMCs with
OTC (2.5 mM; +OTC) reversed this inhibition (c). Values are mean ± standard error of the mean (n = 6 replicate wells), ***p < .001, ***p < .01,
*p < .05 versus control; ###p < .001, ##p < .01 versus untreated. Blots shown are representative of experiments performed three times with
different protein sets. GCL, gamma‐glutamylcysteine synthetase; GSH, glutathione; GSS, glutathione synthetase; OTC, 2‐oxothiazolidine‐4‐
carboxylic acid; VSMC, vascular smooth muscle cell
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Cell death via increased VSMC apoptosis has been found to pro-
mote both intimal and medial calcification. Apoptosis is believed to
induce the release of apoptotic bodies, which in addition to containing
high calcium levels, act as nucleation sites for calcification (Proudfoot
et al., 2000; Reynolds et al., 2004). Initial assessment of cell number
and viability showed OTC treatment increased cell number by up to
40% and viability by 85% when compared to untreated cells. From this,
it is reasonable to suggest that the inhibitory effects of OTC on calci-
fication may be via the prevention of cell death. To validate this, we
subsequently assessed apoptosis utilising measurement of annexin V,
an early marker of apoptosis, via flow cytometry. Consistent with
previous findings (Patel, Bourne, Davies et al., 2019), calcifying VSMCs
exhibited a 75% increase in annexin V positive cells which was inhibited
by pretreated with OTC (2.5 mM). Taken together, this suggests that
OTC may act to inhibit calcification via a reduction in apoptosis.
As discussed above, VSMC calcification has been associated with
VSMCs gaining osteoblast‐like characteristics; this transdifferentia-
tion is associated with downregulation of contractile smooth muscle
cell markers (SM22α and ACTA2) and upregulation of osteogenic
markers (Runx2 and OPN) (Mizobuchi et al., 2009; Steitz et al., 2001).
Consistent with these previous findings, expression of proteins for
Runx2 and OPN were upregulated, while SM22α and ACTA2 were
downregulated in calcifying VSMC when compared to noncalcifying
cells cultured for 4 and 7 days. The addition of OTC (2.5 mM) rescued
these cells and reversed transdifferentiation to an osteoblast‐like
cell. Thus, OTC appears to prevent VSMC phenotypic changes to an
osteoblast‐like cell and this is in addition to its effects on pyropho-
sphate homoeostasis and VSMC apoptosis.
Given the beneficial effects of OTC on inhibiting calcification, cell
death, and VSMC transdifferentiation, we assessed potential med-
iators of this effect. As discussed above, OTC is a prodrug of cysteine,
which is the rate‐limiting amino acid for GSH production. GSH within
cells can exist in either the reduced (GSH) or the oxidised form
glutathione disulfide (GSSG). The ratio of GSH/GSSG is 50:1 and is
affected by increased oxidative stress which leads to increased GSSG
formation (Owen & Butterfield, 2010). Calcifying VSMCs exhibited a
significant reduction (90%) in GSH levels and treatment with OTC
was found to rescue GSH levels similar to that in noncalcifying cells.
It is therefore likely that a calcifying environment, containing high
levels of ROS, shifts GSH to the oxidised form to aid in neutralising
oxidative stress and OTC may reverse this by increasing production
of GSH. To ascertain whether reduced GSH is linked to increased
calcification, we employed the commonly used GSH depletion agent,
l‐buthionine‐sulfoximine, which specifically inhibits GCL and shown
to reduce GSH levels at ∼20 μM (Bailey, 1998; Bohl et al., 2012;
Kachadourian, Leitner, & Day, 2007). In calcifying VSMCs,
l‐buthionine‐sulfoximine increased calcium deposition by up to 50%,
suggesting that reductions in GSH induce calcification. The addition
of OTC effectively blocked the inhibition and prevented increased
calcification. Taken together, these findings suggest that reductions
in GSH levels induce calcification and that treatment of VSMCs with
OTC rescues GSH formation, which may subsequently lead to po-
tential reductions in oxidative stress and thus calcification.
The mechanisms leading to reduced GSH in calcifying VSMCs
are not known. As mentioned above, oxidative stress is a known
inducer of VC and it could be that reduced GSH may be due to
increased conversion to GSSG in an attempt to counteract elevated
ROS. However, studies have linked higher oxidative stress to in-
creased GSH via upregulation of GCL, as well as GCL activity
(Rahman et al., 1966; Ravuri, Svineng, & Huseby, 2013). In contrast,
clinical studies have highlighted ageing and certain diseases asso-
ciated with lower GSH levels and reduced synthesis. In diabetic
individuals, insulin deficiency has been shown to downregulate GCL
expression and reduce GSH levels (Lu, 2009). In addition, elevated
glucose has been linked to reduced messenger RNA expression of
GCL in mouse endothelial cells (Urata et al., 1996). In patients with
CKD, GSH levels and GCL activity were found to be significantly
reduced in uremic patients and those on dialysis; however, the
factors behind this effect could not be established (Alhamdani,
2005). We, therefore, wanted to assess if GSH synthesis enzyme
expression was affected in VSMC calcification. Western blot ana-
lysis was performed to determine changes in expression of GCL and
GSS. At Day 7 of culture, expression of both enzymes was down-
regulated in calcifying VSMC compared to noncalcifying cells. and
this could explain the diminished GSH levels observed. From these
findings, we subsequently assessed the effects of OTC on GCLC and
GSS and found that OTC significantly induced the expression of
both enzymes when compared to untreated calcifying cells. In the
case of GCLC, protein expression showed a recovery to a level si-
milar to untreated VSMCs. Thus, OTC may have a dual effect on
GSH, acting via its well‐established role as a cysteine prodrug and
via enhancing GCLC and GSS protein expression. More importantly,
OTC may inhibit calcification of VSMCs through maintaining GSH
levels in cells.
In summary, we have shown for the first time that OTC can
inhibit VSMC calcification via increased NPP activity and pyr-
ophosphate homoeostasis, reduced apoptosis and VSMC transdif-
ferentiation. In addition, OTC was also able to rescue GSH levels
which were diminished in calcifying VASMCs due to the inhibition in
expression of its synthesis enzymes. These enzymes were induced
by OTC. Taken together, our findings indicate that OTC could be a
novel inhibitor of AMC and could provide potential clinical solutions
for patients susceptible to calcification. For this to be the case, the
concentrations of OTC used in our studies should reflect those
achievable in vivo. On the basis of previous OTC dosage regimes
from clinical trials that were not associated with adverse effects,
single intravenous doses led to levels of OTC of between 6 and
9mM (Bernard et al., 1997; Kalayjian et al., 1994). These con-
centrations are well above the 1–5mM used in our experiments and
gives confidence that OTC may be effective in inhibiting calcifica-
tion in vivo and may do so at lower doses than have been utilised
clinically.
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